David Š.
- Country
- Czechia
- Department
- Interní hematologická a onkologická klinika
Research Overview
- Phase 3 Randomized Double‑Blind Trial of Orelabrutinib Combined with Rituximab and Bendamustine versus Rituximab‑Bendamustine in Treatment‑Naïve Mantle Cell Lymphoma
- Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)
- Randomized European Trial of Autologous Transplantation with Rituximab, Ibrutinib, and Ara-C Induction in Generalized Mantle Cell Lymphoma
Data & Insights
Has run more than one trial at 121 of 310 partner sites.
Specializations
Lymphoma Specialization
The investigator demonstrates specialized expertise in treating mantle cell lymphoma (MCL), with particular focus on innovative therapeutic approaches for both untreated and generalized cases.
- High-risk MCL management
- Novel therapeutic strategies
- Advanced lymphoma treatments
Their research encompasses both standard and experimental treatment modalities for lymphoma patients.
Cell-Based Therapies
The investigator has significant involvement in CAR-T-cell treatment research, particularly focusing on its application in high-risk lymphoma cases.
- Cellular immunotherapy
- Advanced biological treatments
- Personalized cell therapy approaches
Their work involves evaluating novel cellular therapeutic strategies against conventional treatment methods.
Combined Treatment Approaches
The investigator explores multi-modal treatment strategies incorporating various therapeutic agents including rituximab, ibrutinib, and transplantation approaches.
- Combination therapy protocols
- Autologous stem cell transplantation
- Maintenance therapy strategies
Their research includes comparative analysis of different treatment combinations and sequences.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.